Financial Statements
for the 1st quarter of fiscal year ending March 31, 2021
(From Apr. 1, 2020 to Jun. 30, 2020)

Summary of consolidated results

JMS Co., Ltd.
Company Code No. 7702

August 7, 2020
1Highlights in Business Results(unit: JPY million)
Apr. - Jun. 2019
Results

Net sales

Apr. - Jun. 2020
Results

Diff.

Year– over – Year

13,494

13,579850.6%

Operating profit

91630

539

586.6%

Ordinary profit

187685498

265.9%

Profit attributable toowners of parent

48659

611

―%

Basic earnings per share

JPY 1.98

JPY 27.05------Exchange Rate(averageduring period)

US Dollar

JPY 109.90

JPY 107.62

EuroJPY 125.15

JPY 120.11

Singapore Dollar

JPY 80.61

JPY 76.21
OverseasJapanProfit‐Increased sales of Blood Bags and AV Fistula
NeedleSales-Increased sales of Examination Gloves and Closed Drug Mixing/Infusion
System “NEO SHIELD”-Decreased sales of Infusion Sets

Increased in sales.
Increased in profit (2nd straight year).

-The influence of sales increase , the improved sales cost ratio and decreased selling, general and administrative expenses, resulting in increase ofthe operating profit and the ordinary profit-The subsidy income of extraordinary income resulted in increase of the profit attributable to owners of parent

2

Summary by segment (geographical area)(unit: JPY million)

JapanSingapore■ Sales incl.
internal transaction■ Sales for third party－ Profit

9,515

9,367

8,757

8,690
551

Apr. - Jun.
2019

■ Sales incl.
internal transaction■ Sales for third party－ Profit■ Sales incl.
internal transaction■ Sales for third party－ Profit

667
587

4,553
Sales
Decreased
1.6%
ProfitIncreased
114.3%

257

5,151

China

Apr. - Jun.
2020

2,853
2,326
247

Apr. - Jun.
2019

278

Sales
Increased
13.1%

329

300
22

ProfitIncreased
12.4%

Apr. - Jun.
2020

ProfitImproved by32million yen(10)Apr. - Jun.
2019

Apr. - Jun.
2020

[Sales] Increased sales of Examination Gloves and[Sales]

Increased sales of Blood bags for West Asia market
raised net sales.

[Sales]Closed Drug Mixing/Infusion System “NEO SHIELD”
were offset by decreased sales of Infusion Sets,
reducing net sales.

[Ordinary Income][Ordinary Income][Ordinary Income]Despite the influence of decrease sales, improved
sales cost ratio and decreased selling, general andadministrative expenses resulted in a profit growth.

The influence of sales increase resulted in a profitgrowth.

Sales
Decreased
12.0%

Decreased sales of Infusion Sets for the Japan
market due to production transfer to the plant in
Philippines reduced net sales.
Despite the influence of decrease sales, thedecrease of labor cost resulted in a profit growth.

*This segment includes Indonesia local subsidiary.

3

Summary by segment (geographical area)(unit: JPY million)

Philippines

Germany■ Sales incl.
internal transaction■ Sales for third party－ Profit

639
492

Sales
Decreased
23.0%

21(49)

ProfitImproved by19 million yen

789

796

789

785

Others■ Sales for third party－ Profit■ Sales incl.
internal transaction■ Sales for third party－ Profit

72
53

Sales
Increased
0.9%

1,289
45

ProfitIncreased
34.7%

947

Sales
Decreased
26.5%

14

ProfitDecreased
69.2%

(69)
Apr. - Jun.
2019

Apr. - Jun.
2020

Apr. - Jun.
2019

Apr. - Jun.
2020

[Sales] Due to a temporary suspension of[Sales][Ordinary Income][Ordinary Income]production activities under the influence of COVID19, decreased sales of Infusion Sets for the Japan
market reduced net sales.

Due to decreased selling, general andadministrative expenses, reduced loss.

Increased sales of AV Fistula Needle raised net sales.

Apr. - Jun.
2019

Apr. - Jun.
2020

*This segment includes business activity ofsubsidiaries in Japan, United States, South Korea andThailand.

The influence of sales increase resulted in a profit
growth.

4

Sales by Business Segment
Apr. – Jun. 2020

Apr. – Jun. 2019

5,286

Others 3.2%

Transfusion
20.2%

5,228
4,260

4,220

Cardiovascular
7.0%

Apr. – Jun.
Apr.
– Jun.
2020
Sales2020
composition

Dialysis31.1%(unit: JPY million)
2,528(57) (1.1)%

Infusion & Nutrition
38.5%

2,749

(40) (0.9)%
1,033

953
384

Infusion & Nutrition

Dialysis

CardiovascularTransfusion

428

Others5

Sales change by Region (Customer's Location)
Others3.1%

Europe9.2%
North America
11.9%
Asia
13.7%

Apr. – Jun.
2020
Sales composition(unit: JPY million)

430

205

13,494
Net
sales

(235)

Apr. - Jun. 2019JapanJapan
62.1%

(267)

(48)13,579

NetsalesIncreased by
JPY 85 million

AsiaNorth America

EuropeOthersApr. - Jun. 2020
6Selling, General and Admin. Expenses(unit: JPY million)
3,362(unit: JPY million)
Apr. - Jun.
2020

Labor Cost

1,487

1,446(41)(2.8)%

Transport

397

434

36

9.1%

R&D

369

328(41)(11.2)%

Depreciation

8984(5)(6.0)%

1,017

853(164)(16.1)%

3,362

3,146(216)(6.4)%

3,146

24.9%

23.2%

Apr. - Jun.
2019

Apr. - Jun.
2020

Year-overYear

Apr. - Jun.
2019

OthersTotalDiff.

[Reasons for change]
Travel expenses and Clinical trial expense for the development of a new productdecreased.

7Ordinary profit : Compared with the previous year
(unit: JPY million)
Increase of
Gross Profit

Decrease of
SGA

Decrease of
Non-operating
profit

47

181
286

Impact ofExchange rate

(17)
The underlined figures exclude impact of exchange rate.

187
Ordinary
profitApr. - Jun. 2019

685

Ordinary
profitIncreased by
JPY 498million

Apr. - Jun. 20208

Forecast for FYE Mar. 2021
(unit: JPY million)FYE Mar. 2020
ResultFYE Mar. 2021
ForecastYear-over-YearNet sales

58,56959,5001.6%

Operating profit

2,314

2,000(13.6)%

Ordinary profit

2,672

2,200(17.7)%

Profit attributable toowners of parent

1,977

1,600(19.1)%

JPY 81.12

JPY 65.62---US Dollar

JPY 108.74

JPY 108Euro

JPY 122.07

JPY 120

Singapore Dollar

JPY 79.28

JPY 78

Basic earnings per share
Exchange Rate(average duringperiod)

9Topics- Received the "Silver Medal of Merit" from the Japanese Red Cross Society.
Jul. 2020- Announcement of disposition of treasury shares as the stock compensation plan with transfer
restrictions.
Jul. 2020- Treatment for refractory skin ulcer using Platelet Collection Sets “CELLAID P Type” is now coveredby insurance.
Apr. 2020

10The Bridge to Good Health Care

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

11